Impacting Quality of Life and Pancreatic Cancer Survivorship Through a Telehealth Intervention
Latest Information Update: 11 Nov 2024
At a glance
- Drugs MVA CMV (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 06 Nov 2024 Planned End Date changed from 20 Jul 2027 to 3 May 2027.
- 06 Nov 2024 Planned primary completion date changed from 20 Jul 2027 to 3 May 2027.
- 06 Nov 2024 Status changed from not yet recruiting to recruiting.